Corrigendum to "Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics" [Regul. Toxicol. Pharmacol. (2017) 221-230]

Affiliations

¹ Safety Assessment, Genentech, Inc., South San Francisco, CA, United States. Electronic address: cdezafra@amgen.com.
² Preclinical Safety, Novartis Institutes for BioMedical Research, Cambridge, MA, United States.
³ Nonclinical and Translational Sciences, Allergan, Irvine, CA, United States.
⁴ Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
⁵ Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, Cambridge, MA, United States.
⁶ Safety Assessment, Genentech, Inc., South San Francisco, CA, United States.

Published Erratum

Christina L Zuch de Zafra et al. Regul Toxicol Pharmacol. 2017 Aug.

. 2017 Aug:88:364.

doi: 10.1016/j.yrtph.2017.04.006. Epub 2017 Apr 18.

¹ Safety Assessment, Genentech, Inc., South San Francisco, CA, United States. Electronic address: cdezafra@amgen.com.
² Preclinical Safety, Novartis Institutes for BioMedical Research, Cambridge, MA, United States.
³ Nonclinical and Translational Sciences, Allergan, Irvine, CA, United States.
⁴ Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
⁵ Drug Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, Cambridge, MA, United States.
⁶ Safety Assessment, Genentech, Inc., South San Francisco, CA, United States.

No abstract available

Erratum for

Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
de Zafra CLZ, Sasseville VG, Matsumoto S, Freichel C, Milton M, MacLachlan TK, Farman C, Raymond I, Gupta S, Newton R, Atzpodien EA, Thackaberry EA. de Zafra CLZ, et al. Regul Toxicol Pharmacol. 2017 Jun;86:221-230. doi: 10.1016/j.yrtph.2017.03.013. Epub 2017 Mar 16. Regul Toxicol Pharmacol. 2017. PMID: 28322894